[email protected]  ·  +86 133 2121 6666 FDA / CE / RoHS / SGS certified
Buyer guide

IPL or Q-Switched Laser for Pigmentation: Depth Decides

Choosing IPL or Q-switched laser for pigmentation comes down to one question: how deep the melanin sits. Filtered light clears epidermal pigment such as freckles and solar lentigines, while dermal pigment, tattoo ink and mixed lesions need the nanosecond photoacoustic pulse only a Q-switched laser produces. Guess the lesion depth and you either waste a course of sessions or injure a face.

Where the pigment sits decides everything

Our engineering archive sorts lesions by histology, and the word lentigo hides two of them. Freckles: melanocytes increased in the epidermis, 1 to 2 mm yellowish-brown spots on exposed skin, tied to sunshine and season. Solar lentigines, the sun spots on hands and cheekbones, are sun-acquired too, and the archive groups them with freckles for contact-cooled IPL. Its Lentigo chapter means something else: lentigo simplex, macules present from birth or infancy, unrelated to sun or season. All three sit in the epidermis and begin with filtered light.

Colour leads in consultation. Brown and tan read epidermal; blue and slate-grey mean pigment sitting deep, as in nevus of Ota. A Wood's lamp belongs here, before anybody sells a course of ten.

What filtered light does well, and where it stops

An IPL handpiece is a xenon flashlamp behind coated glass. StatPearls puts intense pulsed light at roughly 400 to 1400 nm, polychromatic, with cut-off filters stripping shorter wavelengths so the beam leans toward one chromophore. Our manuals put the Pmise MF-05 at 530 to 1200 nm filtered, 10 to 45 J/cm2.

Why does that suit surface pigment? Short wavelengths are absorbed hard by melanin and travel almost nowhere: useless when the target is deep, ideal on a freckle. Our archive names IPL best for freckles, first choice for lentigo.

One detail buyers skip. The archive is blunt that epidermal pigmented lesions treated with anything other than a Q-switched laser need epidermal cooling, and that with long-pulse devices such as IPL and E-Light, no cooling may mean no clinical effect at all. Sapphire contact cooling pre-chilled to 4 degrees Celsius or lower is what our manuals specify, and the archive prefers it to a cryogen spray, whose synchronisation is unforgiving and whose coolant is a running cost. See the Pmise MF-05 E-Light IPL and RF platform.

Where nanosecond pulses take over

Anderson and Parrish set the rule out in Science in 1983: pick a wavelength the target absorbs better than its neighbours, keep the pulse shorter than the time it needs to shed heat, and only the target is damaged. A melanosome is tiny and cools fast. Milliseconds are hopeless.

That gap is what a Q-switched laser fills. The Pmise QE-01 Q-switched Nd:YAG platform is published at 5 to 7 ns, 1064 nm and 532 nm, up to 14 J/cm2 and 6 J/cm2, spot 1 to 8 mm. Energy has nowhere to go on that timescale, so the granule fractures instead of cooking. Macrophages clear the debris over weeks, so intervals are biology, not diary.

Wavelength choice inside the platform matters too. Our archive has 532 nm absorbed strongly by red and brown targets, 1064 nm by black and blue, penetration rising with wavelength, and a bigger spot reaching deeper at equal energy density, so dermal pigment is worked above 2 mm.

Matching the platform to the lesion

Depth is the sorting key, and a trap sits inside it: epidermal doesn't automatically mean IPL. Cafe-au-lait macules are epidermal by histology, yet our archive calls for a Q-switched laser under 7 ns with single-pulse energy above 400 mJ, and writes off output under 100 mJ as nearly ineffective.

A second number in the same archive looks like it argues with that. It doesn't. The treating-process guidance opens cafe-au-lait work at 200 mJ, and that is the trial rung: you read tolerance and tissue response there, not clearance. From it you climb toward the above-400 mJ band the archive counts as effective, and you never sit under 100 mJ. One ladder, three marks.

Does the machine clear that bar? Comfortably. Our EO Q-switched manual lists single-pulse energy up to 850 mJ at 1064 nm and 600 mJ at 532 nm, pulse width 6 ns. Fluence is energy divided by spot area, the manual's own formula, so a J/cm2 headline settles no per-pulse question.

LesionWhere the pigment sitsFirst line in our archive
FrecklesEpidermisIPL or E-Light, epidermal cooling required
Solar lentigines (sun spots)EpidermisContact-cooled IPL or E-Light
Lentigo simplexBasal layer of the epidermisIPL first; big-spot Q-switched at 400 mJ single pulse if stubborn
Cafe-au-lait maculesEpidermisQ-switched, under 7 ns; start 200 mJ, titrate above 400 mJ to clear
Nevus of Ota, nevus of ItoDermisQ-switched Nd:YAG at 1064 nm, from 400 mJ
Zygomatic maculesDermisQ-switched Nd:YAG at 1064 nm, spot above 4 mm, from 200 mJ
Blue nevusDeep dermis, melanocytic tumourNo device first: clinical and histological confirmation; our archive excises above 1 cm
Tattoo inkDermisQ-switched: 1064 nm for deep, black and blue ink; 532 nm for red
MelasmaEpidermis, dermis, or bothNeither, until diagnosis is confirmed and a test patch is read

One row points away from the machine on purpose. Blue nevus is a melanocytic tumour, dermal melanocytes packed with pigment sitting deep, and our archive names no laser for it: leave small stable lesions alone, excise anything above 1 cm promptly, and treat the cellular variant with real caution, since the archive calls that type liable to worsen into a melanocytic tumour. Histology decides, not a handpiece.

Serious pigment clinics own both boxes, the honest answer for anyone costing out a pigment removal treatment line.

Melasma, referral, and the risks that stay yours

Melasma ruins reputations. Our archive records melanin increased in the epidermis, the dermis, or both, with no self-healing tendency, so nobody names the compartment without looking properly. It calls a trial treatment on a 0.5 to 1 cm2 test area necessary: carry on only if that patch works. Relapse and pigment change are on its complications list.

A 2022 systematic review of low-fluence Q-switched Nd:YAG judged the approach generally effective and reasonably safe, then flagged mottled hypopigmentation linked to high accumulated energy, hyperpigmentation from aggressive use in darker skin, and thin long-term follow-up. Sell a machine on melasma and you sell a maintenance programme nobody agreed to.

Any pigmented lesion with atypical features goes to a clinician before a device is switched on. Not ideally. Before. Delker and colleagues, in the Journal of Dermatology in 2017, described 11 patients at a German university hospital in whom melanoma was diagnosed in an area previously treated by laser; in 82 percent no histological assessment had been done first. Asymmetry, irregular border, changing colour, growth over weeks: referral, not booking. Blue nevus belongs in that queue too.

Two risks travel with every protocol. Post-inflammatory hyperpigmentation is the first, listed in our archive as an occasional complication even of correctly performed Q-switched treatment, alongside occasional scarring. Phototype is the second. StatPearls calls IPL particularly challenging on darker skin, and our parameter sheet steps the pigment programme from 4 to 5 pulses at Fitzpatrick type I down to 2 to 3 from type III, energy falling with it.

Patch test, wait, read the skin rather than the sales sheet. This page is educational material for equipment buyers, not medical advice.

What else to check before you buy

Cooling is the first ownership question, and a fluence quoted with no cooling method is half a spec sheet. Running costs come next. Our maintenance manual rates the E-Light xenon lamp at about 60,000 shots, warns hair-removal results fall short of ideal from roughly 30,000, and changes the cored water filter every two months. Ask who relamps a handpiece, and how long the room stands idle.

Who holds the handpiece matters too. Our Q-switched manual says a professional beautician, dermatologist or doctor should perform the treatment, and your regulator decides who may legally run each class of device. Ask every supplier for the same papers:

  • Certification valid in your market, naming the model quoted.
  • Per-pulse energy and measured pulse width at each wavelength and spot size.
  • The cooling method, and what it consumes.
  • Lamp or handpiece rated life, and where relamping happens.
  • Warranty term, response time and training, in writing, before the deposit.

Salon buyers: ask us for the MF-05 filter, cooling and phototype parameter sheet. Clinics and distributors: request a quotation or distributor enquiry naming the spot sizes you'll run, so per-pulse energy comes back with the price.

Questions buyers ask

If I can only afford one machine, which one?

Look at your appointment book, not the brochure. A salon whose Saturdays are freckles, sun damage, hair reduction and facial redness bills more hours from an IPL or E-Light platform: one box answers four requests. A clinic with a doctor on staff, dermal lesions and tattoo enquiries needs the Q-switched laser, and nothing substitutes.

How many sessions should I quote a patient?

Clearance is gradual on both platforms. Our manuals give cafe-au-lait macules 6 to 8 sessions at 45 to 60 day intervals, nevus of Ota 6 to 8 at 60 to 90 days. Epidermal spots under filtered light usually need several sessions. Quote the course, say plainly that some lesions plateau, never quote one visit.

Does darker skin change the answer?

It narrows the margin rather than closing the door. Epidermal melanin competes for every photon, so type V punishes a setting that suited type II. StatPearls prefers longer wavelengths as the phototype rises, and our Q-switched manual splits cafe-au-lait work the same way: 532 nm for types II and III, 1064 nm from type III. Either wavelength opens at that same 200 mJ trial rung and climbs toward the above-400 mJ clearance band. Skin type moves the wavelength, not the ladder.

Evidence & further reading

Educational material for equipment selection and operator training. It is not medical advice, a treatment protocol or a promise of clinical outcome.